Medicine and Dentistry
Mycosis fungoides
92%
Diseases
57%
Cutaneous Lymphoma
45%
Melanoma
34%
Psoriasis
24%
Dermatology
22%
Metastatic Melanoma
20%
Cutaneous T Cell Lymphoma
20%
Tumor
20%
Phototherapy
19%
Treatment Option
17%
Neoplasm
17%
Cancer Treatment
16%
B Cell
15%
Skin Carcinoma
15%
Pediatrics
15%
Retrospective Study
15%
Clinical Trial
15%
Quality of Life
13%
Overall Survival
12%
Apoplexy
12%
Prevalence
12%
Biological Product
11%
Cancer
11%
Keratinocyte
10%
Interleukin 23p19
10%
T Cell
9%
Oncology
9%
Medicine
9%
Kidney Transplantation
8%
Melanoma Cell
8%
Carcinogenesis
8%
Skin Cancer
8%
PUVA
8%
Patient Characteristics
8%
Epithelioma
7%
Proteochondroitin Sulfate
7%
Hypoxia Inducible Factor 1
7%
Therapy Resistance
7%
Tumour Heterogeneity
7%
Sorafenib
7%
DNA Repair
7%
Vasculotropin
7%
Cushing Disease
7%
Carney Complex
7%
Cancer Therapy
7%
Leg Ulcer
7%
T-Cell Lymphoma
7%
RNA Sequence
7%
Hepatocellular Carcinoma
7%
Clusterin
7%
Outpatient
7%
Platelet
7%
Cross Sectional Study
7%
Actinic Keratosis
7%
Skin Biopsy
7%
Notch Signaling
7%
Pancreatitis
7%
Fibrinogen
7%
Mammalian Cell
7%
Lymphocyte
7%
Polyarthritis
7%
Lupus Erythematosus Panniculitis
7%
Interleukin 23 Antibody
7%
Volunteer
7%
Medical Research
7%
Human Subject
7%
Real-World Evidence
7%
Pustulosis Palmaris Et Plantaris
7%
Hazard Ratio
7%
Aminolevulinic Acid
7%
Pathogen
7%
Nonsense Mutation
7%
Sneddon Syndrome
7%
Risk Stratification
7%
Pediatric Stroke
7%
Soft Tissue Infection
7%
Neutrophil
7%
Patient Referral
7%
Programmed Death 1 Receptor
7%
Melanocytosis
7%
Hematologic Malignancy
7%
Notch
7%
Diabetic Foot Ulcer
7%
Peripheral Blood Mononuclear Cell
7%
Placebo
7%
Pseudomonas aeruginosa
7%
Nivolumab
7%
Predictive Factor
7%
Uvomorulin
7%
Allergology
7%
Hemosiderin
7%
Pigmentation
7%
Registry Analysis
7%
Cohort Effect
7%
Calciphylaxis
7%
Biopsy Technique
7%
Progression Free Survival
7%
Wound
6%
In Vitro
6%
Immunology and Microbiology
Immunoglobulin E
100%
Allergen
93%
Birch Pollen
24%
T Cell
24%
Allergenicity
24%
Sensitization
23%
Cross-Reactivity
20%
Epitope
18%
Molecular Weight
18%
ELISA
17%
B Cell
16%
Melanoma Cell
16%
Transcriptomics
15%
Neutrophil
15%
Holocephali
15%
Basophil
15%
Escherichia coli
15%
Extract
13%
Peptides
11%
Immunoglobulin E Antibody
11%
Hypersensitive Response
10%
Proteomics
10%
Legumin
10%
Western Blot
9%
Protein Binding
8%
RNA Sequence
8%
Squamous Cell
8%
Allergen Specific Immunotherapy
8%
Proinflammatory Cytokine
8%
Basophil Activation
8%
Pustulosis
7%
Biological Product
7%
Psoriatic Arthritis
7%
Talimogene Laherparepvec
7%
Permeability Barrier
7%
TNF Inhibitor
7%
Adalimumab
7%
Kidney Transplantation
7%
Cell Invasion
7%
Notch
7%
Heat Shock
7%
Nicotiana benthamiana
7%
Mastocytosis
7%
Sorafenib
7%
Fibrinogen
7%
Lactobacillus buchneri
7%
Antigen Presentation
7%
Nose Mucosa
7%
Anura
7%
Structural Characteristics
7%
Muscle
7%
Notch Signaling
7%
Programmed Death-Ligand 1
7%
Platelet
7%
Salmon
7%
Salmonine
7%
Chondroitin Sulfate Proteoglycan
7%
Monoclonal Antibody
7%
Tumor Spheroid
7%
Lymphocyte
7%
Infectious Agent
7%
Solid Organ Transplantation
7%
Mast Cell
7%
Infection
7%
Food Allergy
7%
Immunotherapy
7%
Calcium Binding
7%
Pseudomonas aeruginosa
7%
DNA Repair
7%
Etanercept
7%
Soft Tissue
7%
Cadherin
7%
Immune System
7%
Mediator
7%
Infliximab
6%
Cross-Reactive Carbohydrate Determinants
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
41%
Diseases
32%
Melanoma
31%
Biological Product
24%
Survival Rate
18%
Mycosis fungoides
15%
Skin Cancer
15%
Epithelium Tumor
15%
Skin Carcinoma
15%
Retrospective Study
14%
Nivolumab
14%
Progression Free Survival
13%
Psoriasis Vulgaris
13%
Etanercept
13%
Adalimumab
13%
Clinical Trial
12%
Combination Therapy
12%
Adverse Event
11%
Overall Survival
11%
Ustekinumab
10%
Metastatic Melanoma
10%
Interleukin 23p19
10%
Psoriatic Arthritis
10%
Mitogen Activated Protein Kinase Kinase Inhibitor
10%
Cutaneous T Cell Lymphoma
9%
Pustulosis palmoplantaris
9%
Recurrent Disease
9%
Trametinib
8%
Dabrafenib
8%
Pembrolizumab
8%
Talimogene Laherparepvec
7%
Apremilast
7%
Aminolevulinic Acid
7%
Hemosiderin
7%
Tumor Necrosis Factor Inhibitor
7%
Chondroitin Sulfate
7%
Interleukin 23 Antibody
7%
Secukinumab
7%
Interleukin 17 Antibody
7%
Ixekizumab
7%
EC50
7%
Cyclorphan
7%
Lactobacillus buchneri
7%
Pustular Psoriasis
7%
Acute Generalized Exanthematous Pustulosis
7%
Pustulosis
7%
Fibrinogen
7%
Heat Shock Protein 27
7%
Hematologic Malignancy
7%
Defined Daily Dose
7%
Immunoglobulin E
7%
Allergen
7%
Immunotherapy
7%
Programmed Death 1 Receptor
7%
Clusterin
7%
Peanut
7%
Hypoxia Inducible Factor 1
7%
Infectious Agent
7%
Vasculotropin
7%
Placebo
7%
Infliximab
6%
Carotid Artery Obstruction
6%
Messenger RNA
6%
Cohort Study
6%
Cancer Staging
6%
Neoplasm
5%
Tolerability
5%
Soft Tissue Infection
5%
Pseudomonas aeruginosa
5%
Malignant Neoplasm
5%
Chimeric Protein
5%
Wound
5%
Antiinfective Agent
5%